Sélectionner une page

Abderrahim LACHGAR

CEO

Immunotherapy, Inflammation, IBD, Ulcerative Colitis

Par’Immune is a clinical-stage biopharmaceutical company founded in late 2017.
Building upon 20 years of the academic research & clinical activities around the parasite-derived P28GST protein, Par’Immune aims to further develop innovative First-In-Class medicines against aggressive inflammatory auto-immune disorders. Whilst primary focus will be on a rare indication the company will also target broader chronic inflammatory diseases with significant unmet needs such as Ulcerative Colitis (UC). Par’Immune plans to initiate Phase 2b trials early in 2020